TTrofinetide· Health · 7 sources · 8hStoryAcadia expects Rett drug protection through 2041Acadia Pharmaceuticals received a U.S. patent allowance covering weight-banded dosing of trofinetide, the active ingredient in DAYBUE and DAYBUE STIX for Rett syndrome. Including pediatric exclusivity, the patent is expected to extend U.S. protection to March 28, 2041—nearly five years beyond existing method-of-use protection.Health· 8h+42ShareMaya Lindstrom·40mTop commentFive more years of exclusivity on DAYBUE might limit access for patients who need weight-based dosing options.00ReplyGenius replyShareWrite a comment…
